These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29023241)

  • 1. Estimating Causal Effects of Treatment in a Randomized Trial When Some Participants Only Partially Adhere.
    Shrier I; Platt RW; Steele RJ; Schnitzer M
    Epidemiology; 2018 Jan; 29(1):78-86. PubMed ID: 29023241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple Estimation of Patient-Oriented Effects From Randomized Trials: An Open and Shut CACE.
    Steele RJ; Shrier I; Kaufman JS; Platt RW
    Am J Epidemiol; 2015 Sep; 182(6):557-66. PubMed ID: 26283090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond intention to treat: what is the right question?
    Shrier I; Steele RJ; Verhagen E; Herbert R; Riddell CA; Kaufman JS
    Clin Trials; 2014 Feb; 11(1):28-37. PubMed ID: 24096636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and robustness of causal effect estimators when noncompliance is measured with error.
    Boatman JA; Vock DM; Koopmeiners JS
    Stat Med; 2018 Dec; 37(28):4126-4141. PubMed ID: 30109713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting approaches for addressing non-adherence in randomized controlled trials: An illustration from the REFLUX trial.
    Keele L; Grieve R
    Clin Trials; 2022 Feb; 19(1):97-106. PubMed ID: 34949104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple imputation methods for treatment noncompliance and nonresponse in randomized clinical trials.
    Taylor L; Zhou XH
    Biometrics; 2009 Mar; 65(1):88-95. PubMed ID: 18397338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating causal effects using prior information on nontrial treatments.
    Bond SJ; White IR
    Clin Trials; 2010 Dec; 7(6):664-76. PubMed ID: 20817650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarifying selection bias in cluster randomized trials.
    Li F; Tian Z; Bobb J; Papadogeorgou G; Li F
    Clin Trials; 2022 Feb; 19(1):33-41. PubMed ID: 34894795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and inference for the intent-to-treat principle using adaptive treatment.
    Dawson R; Lavori PW
    Stat Med; 2015 Apr; 34(9):1441-53. PubMed ID: 25581413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the Effect of a Treatment When There Is Nonadherence in a Trial.
    Richardson DB; Dukes O; Tchetgen Tchetgen EJ
    Am J Epidemiol; 2023 Oct; 192(10):1772-1780. PubMed ID: 37338999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating partial adherence into the principal stratification analysis framework.
    Sanders E; Gustafson P; Karim ME
    Stat Med; 2021 Jul; 40(15):3625-3644. PubMed ID: 33880769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating causal effects of treatment in RCTs with provider and subject noncompliance.
    Sheng E; Li W; Zhou XH
    Stat Med; 2019 Feb; 38(5):738-750. PubMed ID: 30347462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Intention-to-treat Principle in Randomized Controlled Trials.
    McCoy CE
    West J Emerg Med; 2017 Oct; 18(6):1075-1078. PubMed ID: 29085540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model misspecification sensitivity analysis in estimating causal effects of interventions with non-compliance.
    Jo B
    Stat Med; 2002 Nov; 21(21):3161-81. PubMed ID: 12375297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disentangling estimands and the intention-to-treat principle.
    Leuchs AK; Brandt A; Zinserling J; Benda N
    Pharm Stat; 2017 Jan; 16(1):12-19. PubMed ID: 27910217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using marginal structural models to analyze randomized clinical trials with non-adherence and lost to follow up.
    Lancet EA; Borrell LN; Holbrook J; Morabia A
    Ann Epidemiol; 2021 Nov; 63():22-28. PubMed ID: 34289408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials.
    Murray EJ; Caniglia EC; Swanson SA; Hernández-Díaz S; Hernán MA
    J Clin Epidemiol; 2018 Nov; 103():10-21. PubMed ID: 29966732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using structural-nested models to estimate the effect of cluster-level adherence on individual-level outcomes with a three-armed cluster-randomized trial.
    Brumback BA; He Z; Prasad M; Freeman MC; Rheingans R
    Stat Med; 2014 Apr; 33(9):1490-502. PubMed ID: 24288357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance.
    Loeys T; Goetghebeur E
    Biometrics; 2003 Mar; 59(1):100-5. PubMed ID: 12762446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.